A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidde
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh